Tag Archives: AbCellera

The 2023 Canadian federal budget: science & technology of health, the clean economy, reconciliation, and more (1 of 2)

The Canadian federal government released its 2023 budget on Tuesday, March 28, 2023. There were no flashy science research announcements in the budget. Trudeau and his team like to trumpet science initiatives and grand plans (even if they’re reannouncing something from a previous budget) but like last year—this year—not so much.

Consequently, this posting about the annual federal budget should have been shorter than usual. What happened?

Partly, it’s the military spending (chapter 5 of the budget in part 2 of this 2023 budget post). For those who are unfamiliar with the link between military scientific research and their impact on the general population, there are a number of inventions and innovations directly due to military research, e.g., plastic surgery, television, and the internet. (You can check a November 6, 2018 essay for The Conversation by Robert Kirby, Professor of Clinical Education and Surgery at Keele University, for more about the impact of World War 1 and medical research, “World War I: the birth of plastic surgery and modern anaesthesia.”)

So, there’s a lot to be found by inference. Consequently, I found Chapter 3 to also be unexpectedly rich in science and technology efforts.

Throughout both parts of this 2023 Canadian federal budget post, you will find excerpts from individual chapters of the federal budget followed my commentary directly after. My general commentary is reserved for the end.

Sometimes, I have included an item because it piqued my interest. E.g., Canadian agriculture is dependent on Russian fertilizer!!! News to me and I imagine many others. BTW, this budget aims to wean us from this dependency.

Chapter 2: Investing in Public Health Care and Affordable Dental Care

Here goes: from https://www.budget.canada.ca/2023/report-rapport/toc-tdm-en.html,

2.1 Investing in Public Health Care

Improving Canada’s Readiness for Health Emergencies

Vaccines and other cutting-edge life-science innovations have helped us to take control of the COVID-19 pandemic. To support these efforts, the federal government has committed significant funding towards the revitalization of Canada’s biomanufacturing sector through a Biomanufacturing and Life Sciences Strategy [emphasis mine]. To date, the government has invested more than $1.8 billion in 32 vaccine, therapeutic, and biomanufacturing projects across Canada, alongside $127 million for upgrades to specialized labs at universities across the country. Canada is building a life sciences ecosystem that is attracting major investments from leading global companies, including Moderna, AstraZeneca, and Sanofi.

To build upon the progress of the past three years, the government will explore new ways to be more efficient and effective in the development and production of the vaccines, therapies, and diagnostic tools that would be required for future health emergencies. As a first step, the government will further consult Canadian and international experts on how to best organize our readiness efforts for years to come. …

Gold rush in them thar life sciences

I have covered the rush to capitalize on Canadian life sciences research (with a special emphasis on British Columbia) in various posts including (amongst others): my December 30, 2020 posting “Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist,” and my August 23, 2021 posting “Who’s running the life science companies’ public relations campaign in British Columbia (Vancouver, Canada)?” There’s also my August 20, 2021 posting “Getting erased from the mRNA/COVID-19 story,” highlighting how brutal the competition amongst these Canadian researchers can be.

Getting back to the 2023 budget, ‘The Biomanufacturing and Life Sciences Strategy’ mentioned in this latest budget was announced in a July 28, 2021 Innovation, Science and Economic Development Canada news release. You can find the strategy here and an overview of the strategy here. You may want to check out the overview as it features links to,

What We Heard Report: Results of the consultation on biomanufacturing and life sciences capacity in Canada

Ontario’s Strategy: Taking life sciences to the next level

Quebec’s Strategy: 2022–2025 Québec Life Sciences Strategy

Nova Scotia’s Strategy: BioFuture2030 Prince Edward Island’s Strategy:

The Prince Edward Island Bioscience Cluster [emphases mine]

2022 saw one government announcement concerning the strategy, from a March 3, 2022 Innovation, Science and Economic Development Canada news release, Note: Links have been removed,

Protecting the health and safety of Canadians and making sure we have the domestic capacity to respond to future health crises are top priorities of the Government of Canada. With the guidance of Canada’s Biomanufacturing and Life Sciences Strategy, the government is actively supporting the growth of a strong, competitive domestic life sciences sector, with cutting-edge biomanufacturing capabilities.

Today [March 3, 2022], the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a $92 million investment in adMare BioInnovations to drive company innovation, scale-up and training activities in Canada’s life sciences sector. This investment will help translate commercially promising health research into innovative new therapies and will see Canadian anchor companies provide the training required and drive the growth of Canada’s life science companies.

The real action took place earlier this month (March 2023) just prior to the budget. Oddly, I can’t find any mention of these initiatives in the budget document. (Confession: I have not given the 2023 budget a close reading although I have been through the whole budget once and viewed individual chapters more closely a few times.)

This March 2, 2023 (?) Tri-agency Institutional Programs Secretariat news release kicked things off, Note 1: I found the date at the bottom of their webpage; Note 2: Links have been removed,

The Government of Canada’s main priority continues to be protecting the health and safety of Canadians. Throughout the pandemic, the quick and decisive actions taken by the government meant that Canada was able to scale up domestic biomanufacturing capacity, which had been in decline for over 40 years. Since then, the government is rebuilding a strong and competitive biomanufacturing and life sciences sector brick by brick. This includes strengthening the foundations of the life sciences ecosystem through the research and talent of Canada’s world-class postsecondary institutions and research hospitals, as well as fostering increased collaboration with innovative companies.

Today [March 2, 2023?], the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs [emphasis mine]:

  • CBRF PRAIRIE Hub, led by the University of Alberta
  • Canada’s Immuno-Engineering and Biomanufacturing Hub, led by The University of British Columbia
  • Eastern Canada Pandemic Preparedness Hub, led by the Université de Montréal
  • Canadian Pandemic Preparedness Hub, led by the University of Ottawa and McMaster University
  • Canadian Hub for Health Intelligence & Innovation in Infectious Diseases, led by the University of Toronto

This investment, made through Stage 1 of the integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) competition, will bolster research and talent development efforts led by the institutions, working in collaboration with their partners. The hubs combine the strengths of academia, industry and the public and not-for-profit sectors to jointly improve pandemic readiness and the overall health and well-being of Canadians.

The multidisciplinary research hubs will accelerate the research and development of next-generation vaccines and therapeutics and diagnostics, while supporting training and development to expand the pipeline of skilled talent. The hubs will also accelerate the translation of promising research into commercially viable products and processes. This investment helps to strengthen the resilience of Canada’s life sciences sector by supporting leading Canadian research in innovative technologies that keep us safe and boost our economy.

Today’s [March 2, 2023?] announcement also launched Stage 2 of the CBRF-BRIF competition. This is a national competition that includes $570 million in available funding for proposals, aimed at cutting-edge research, talent development and research infrastructure projects associated with the selected research hubs. By strengthening research and talent capacity and leveraging collaborations across the entire biomanufacturing ecosystem, Canada will be better prepared to face future pandemics, in order to protect Canadian’s health and safety. 

Then, the Innovation, Science and Economic Development Canada’s March 9, 2023 news release made this announcement, Note: Links have been removed,

Since March 2020, major achievements have been made to rebuild a vibrant domestic life sciences ecosystem to protect Canadians against future health threats. The growth of the sector is a top priority for the Government of Canada, and with over $1.8 billion committed to 33 projects to boost our domestic biomanufacturing, vaccine and therapeutics capacity, we are strengthening our resiliency for current health emergencies and our readiness for future ones.

The COVID-19 Vaccine Task Force played a critical role in guiding and supporting the Government of Canada’s COVID-19 vaccine response. Today [March 9, 2023], recognizing the importance of science-based decisions, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, are pleased to announce the creation of the Council of Expert Advisors (CEA). The 14 members of the CEA, who held their first official meeting earlier this week, will advise the Government of Canada on the long-term, sustainable growth of Canada’s biomanufacturing and life sciences sector, and on how to enhance our preparedness and capacity to protect the health and safety of Canadians.

The membership of the CEA comprises leaders with in-depth scientific, industrial, academic and public health expertise. The CEA co-chairs are Joanne Langley, Professor of Pediatrics and of Community Health and Epidemiology at the Dalhousie University Faculty of Medicine, and Division Head of Infectious Diseases at the IWK Health Centre; and Marco Marra, Professor in Medical Genetics at the University of British Columbia (UBC), UBC Canada Research Chair in Genome Science and distinguished scientist at the BC Cancer Foundation.

The CEA’s first meeting focused on the previous steps taken under Canada’s Biomanufacturing and Life Sciences Strategy and on its path forward. The creation of the CEA is an important milestone in the strategy, as it continues to evolve and adapt to new technologies and changing conditions in the marketplace and life sciences ecosystem. The CEA will also inform on investments that enhance capacity across Canada to support end-to-end production of critical vaccines, therapeutics and essential medical countermeasures, and to ensure that Canadians can reap the full economic benefits of the innovations developed, including well-paying jobs.

As I’m from British Columbia, I’m highlighting this University of British Columbia (UBC) March 17, 2023 news release about their involvement, Note: Links have been removed,

Canada’s biotech ecosystem is poised for a major boost with the federal government announcement today that B.C. will be home to Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH).

The B.C.-based research and innovation hub, led by UBC, brings together a coalition of provincial, national and international partners to position Canada as a global epicentre for the development and manufacturing of next-generation immune-based therapeutics.

A primary goal of CIEBH is to establish a seamless drug development pipeline that will enable Canada to respond to future pandemics and other health challenges in fewer than 100 days.

This hub will build on the strengths of B.C.’s biotech and life sciences industry, and those of our national and global partners, to make Canada a world leader in the development of lifesaving medicines,” said Dr. Deborah Buszard, interim president and vice-chancellor of UBC. “It’s about creating a healthier future for all Canadians. Together with our outstanding alliance of partners, we will ensure Canada is prepared to respond rapidly to future health challenges with homegrown solutions.”

CIEBH is one of five new research hubs announced by the federal government that will work together to improve pandemic readiness and the overall health and well-being of Canadians. Federal funding of $570 million is available over the next four years to support project proposals associated with these hubs in order to advance Canada’s Biomanufacturing and Life Sciences Strategy.

More than 50 organizations representing the private, public, not-for-profit and academic sectors have come together to form the hub, creating a rich environment that will bolster biomedical innovation in Canada. Among these partners are leading B.C. biotech companies that played a key role in Canada’s COVID-19 pandemic response and are developing cutting-edge treatments for a range of human diseases.

CIEBH, led by UBC, will further align the critical mass of biomedical research strengths concentrated at B.C. academic institutions, including the B.C. Institute of Technology, Simon Fraser University and the University of Victoria, as well as the clinical expertise of B.C. research hospitals and health authorities. With linkages to key partners across Canada, including Dalhousie University, the University of Waterloo, and the Vaccine and Infectious Disease Organization, the hub will create a national network to address gaps in Canada’s drug development pipeline.

In recent decades, B.C. has emerged as a global leader in immuno-engineering, a field that is transforming how society treats disease by harnessing and modulating the immune system.

B.C. academic institutions and prominent Canadian companies like Precision NanoSystems, Acuitas Therapeutics and AbCellera have developed significant expertise in advanced immune-based therapeutics such as lipid nanoparticle- and mRNA-based vaccines, engineered antibodies, cell therapies and treatments for antimicrobial resistant infections. UBC professor Dr. Pieter Cullis, a member of CIEBH’s core scientific team, has been widely recognized for his pioneering work developing the lipid nanoparticle delivery technology that enables mRNA therapeutics such as the highly effective COVID-19 mRNA vaccines.

As noted previously, I’m a little puzzled that the federal government didn’t mention the investment in these hubs in their budget. They usually trumpet these kinds of initiatives.

On a related track, I’m even more puzzled that the province of British Columbia does not have its own life sciences research strategy in light of that sector’s success. Certainly it seems that Ontario, Quebec, Nova Scotia, and Prince Edward are all eager to get a piece of the action. Still, there is a Life Sciences in British Columbia: Sector Profile dated June 2020 and an undated (likely from some time between July 2017 to January 2020 when Bruce Ralston whose name is on the document was the relevant cabinet minister) British Columbia Technology and Innovation Policy Framework.

In case you missed the link earlier, see my August 23, 2021 posting “Who’s running the life science companies’ public relations campaign in British Columbia (Vancouver, Canada)?” which includes additional information about the BC life sciences sector, federal and provincial funding, the City of Vancouver’s involvement, and other related matters.

Chapter 3: A Made-In-Canada Plan: Affordable Energy, Good Jobs, and a Growing Clean Economy

The most science-focused information is in Chapter 3, from https://www.budget.canada.ca/2023/report-rapport/toc-tdm-en.html,

3.2 A Growing, Clean Economy

More than US$100 trillion in private capital is projected to be spent between now and 2050 to build the global clean economy.

Canada is currently competing with the United States, the European Union, and countries around the world for our share of this investment. To secure our share of this global investment, we must capitalize on Canada’s competitive advantages, including our skilled and diverse workforce, and our abundance of critical resources that the world needs.

The federal government has taken significant action over the past seven years to support Canada’s net-zero economic future. To build on this progress and support the growth of Canada’s clean economy, Budget 2023 proposes a range of measures that will encourage businesses to invest in Canada and create good-paying jobs for Canadian workers.

This made-in-Canada plan follows the federal tiered structure to incent the development of Canada’s clean economy and provide additional support for projects that need it. This plan includes:

  • Clear and predictable investment tax credits to provide foundational support for clean technology manufacturing, clean hydrogen, zero-emission technologies, and carbon capture and storage;
  • The deployment of financial instruments through the Canada Growth Fund, such as contracts for difference, to absorb certain risks and encourage private sector investment in low-carbon projects, technologies, businesses, and supply chains; and,
  • Targeted clean technology and sector supports delivered by Innovation, Science and Economic Development Canada to support battery manufacturing and further advance the development, application, and manufacturing of clean technologies.

Canada’s Potential in Critical Minerals

As a global leader in mining, Canada is in a prime position to provide a stable resource base for critical minerals [emphasis mine] that are central to major global industries such as clean technology, auto manufacturing, health care, aerospace, and the digital economy. For nickel and copper alone, the known reserves in Canada are more than 10 million tonnes, with many other potential sources at the exploration stage.

The Buy North American provisions for critical minerals and electric vehicles in the U.S. Inflation Reduction Act will create opportunities for Canada. In particular, U.S. acceleration of clean technology manufacturing will require robust supply chains of critical minerals that Canada has in abundance. However, to fully unleash Canada’s potential in critical minerals, we need to ensure a framework is in place to accelerate private investment.

Budget 2022 committed $3.8 billion for Canada’s Critical Minerals Strategy to provide foundational support to Canada’s mining sector to take advantage of these new opportunities. The Strategy was published in December 2022.

On March 24, 2023, the government launched the Critical Minerals Infrastructure Fund [emphasis mine; I cannot find a government announcement/news release for this fund]—a new fund announced in Budget 2022 that will allocate $1.5 billion towards energy and transportation projects needed to unlock priority mineral deposits. The new fund will complement other clean energy and transportation supports, such as the Canada Infrastructure Bank and the National Trade Corridors Fund, as well as other federal programs that invest in critical minerals projects, such as the Strategic Innovation Fund.

The new Investment Tax Credit for Clean Technology Manufacturing proposed in Budget 2023 will also provide a significant incentive to boost private investment in Canadian critical minerals projects and create new opportunities and middle class jobs in communities across the country.

An Investment Tax Credit for Clean Technology Manufacturing

Supporting Canadian companies in the manufacturing and processing of clean technologies, and in the extraction and processing of critical minerals, will create good middle class jobs for Canadians, ensure our businesses remain competitive in major global industries, and support the supply chains of our allies around the world.

While the Clean Technology Investment Tax Credit, first announced in Budget 2022, will provide support to Canadian companies adopting clean technologies, the Clean Technology Manufacturing Investment Tax Credit will provide support to Canadian companies that are manufacturing or processing clean technologies and their precursors.

  • Budget 2023 proposes a refundable tax credit equal to 30 per cent of the cost of investments in new machinery and equipment used to manufacture or process key clean technologies, and extract, process, or recycle key critical minerals, including:
    • Extraction, processing, or recycling of critical minerals essential for clean technology supply chains, specifically: lithium, cobalt, nickel, graphite, copper, and rare earth elements;
    • Manufacturing of renewable or nuclear energy equipment;
    • Processing or recycling of nuclear fuels and heavy water; [emphases mine]
    • Manufacturing of grid-scale electrical energy storage equipment;
    • Manufacturing of zero-emission vehicles; and,
    • Manufacturing or processing of certain upstream components and materials for the above activities, such as cathode materials and batteries used in electric vehicles.

The investment tax credit is expected to cost $4.5 billion over five years, starting in 2023-24, and an additional $6.6 billion from 2028-29 to 2034-35. The credit would apply to property that is acquired and becomes available for use on or after January 1, 2024, and would no longer be in effect after 2034, subject to a phase-out starting in 2032.

3.4 Reliable Transportation and Resilient Infrastructure

Supporting Resilient Infrastructure Through Innovation

The Smart Cities Challenge [emphasis mine] was launched in 2017 to encourage cities to adopt new and innovative approaches to improve the quality of life for their residents. The first round of the Challenge resulted in $75 million in prizes across four winning applicants: Montreal, Quebec; Guelph, Ontario; communities of Nunavut; and Bridgewater, Nova Scotia.

New and innovative solutions are required to help communities reduce the risks and impacts posed by weather-related events and disasters triggered by climate change. To help address this issue, the government will be launching a new round of the Smart Cities Challenge later this year, which will focus on using connected technologies, data, and innovative approaches to improve climate resiliency.

3.5 Investing in Tomorrow’s Technology

With the best-educated workforce on earth, world-class academic and research institutions, and robust start-up ecosystems across the country, Canada’s economy is fast becoming a global technology leader – building on its strengths in areas like artificial intelligence. Canada is already home to some of the top markets for high-tech careers in North America, including the three fastest growing markets between 2016 and 2021: Vancouver, Toronto, and Quebec City.

However, more can be done to help the Canadian economy reach its full potential. Reversing a longstanding trend of underinvestment in research and development by Canadian business [emphasis mine] is essential our long-term economic growth.

Budget 2023 proposes new measures to encourage business innovation in Canada, as well as new investments in college research and the forestry industry that will help to build a stronger and more innovative Canadian economy.

Attracting High-Tech Investment to Canada

In recent months, Canada has attracted several new digital and high-tech projects that will support our innovative economy, including:

  • Nokia: a $340 million project that will strengthen Canada’s position as a leader in 5G and digital innovation;
  • Xanadu Quantum Technologies: a $178 million project that will support Canada’s leadership in quantum computing;
  • Sanctuary Cognitive Systems Corporation: a $121 million project that will boost Canada’s leadership in the global Artificial Intelligence market; and,
  • EXFO: a $77 million project to create a 5G Centre of Excellence that aims to develop one of the world’s first Artificial Intelligence-based automated network solutions.

Review of the Scientific Research and Experimental Development Tax Incentive Program

The Scientific Research and Experimental Development (SR&ED) tax incentive program continues to be a cornerstone of Canada’s innovation strategy by supporting research and development with the goal of encouraging Canadian businesses of all sizes to invest in innovation that drives economic growth.

In Budget 2022, the federal government announced its intention to review the SR&ED program to ensure it is providing adequate support and improving the development, retention, and commercialization of intellectual property, including the consideration of adopting a patent box regime. [emphasis mine] The Department of Finance will continue to engage with stakeholders on the next steps in the coming months.

Modernizing Canada’s Research Ecosystem

Canada’s research community and world-class researchers solve some of the world’s toughest problems, and Canada’s spending on higher education research and development, as a share of GDP, has exceeded all other G7 countries. 

Since 2016, the federal government has committed more than $16 billion of additional funding to support research and science across Canada. This includes:

  • Nearly $4 billion in Budget 2018 for Canada’s research system, including $2.4 billion for the Canada Foundation for Innovation and the granting councils—the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada and the Canadian Institutes of Health Research; [emphases mine]
  • More than $500 million in Budget 2019 in total additional support to third-party research and science organizations, in addition to the creation of the Strategic Science Fund, which will announce successful recipients later this year;
  • $1.2 billion in Budget 2021 for Pan-Canadian Genomics and Artificial Intelligence Strategies, and a National Quantum Strategy;
  • $1 billion in Budget 2021 to the granting councils and the Canada Foundation for Innovation for life sciences researchers and infrastructure; and,
  • The January 2023 announcement of Canada’s intention to become a full member in the Square Kilometre Array Observatory, which will provide Canadian astronomers with access to its ground-breaking data. The government is providing up to $269.3 million to support this collaboration.

In order to maintain Canada’s research strength—and the knowledge, innovations, and talent it fosters—our systems to support science and research must evolve. The government has been consulting with stakeholders, including through the independent Advisory Panel on the Federal Research Support System, to seek advice from research leaders on how to further strengthen Canada’s research support system.

The government is carefully considering the Advisory Panel’s advice, with more detail to follow in the coming months on further efforts to modernize the system.

Using College Research to Help Businesses Grow

Canada’s colleges, CEGEPs, and polytechnic institutes use their facilities, equipment, and expertise to solve applied research problems every day. Students at these institutions are developing the skills they need to start good careers when they leave school, and by partnering with these institutions, businesses can access the talent and the tools they need to innovate and grow.

  • To help more Canadian businesses access the expertise and research and development facilities they need, Budget 2023 proposes to provide $108.6 million over three years, starting in 2023-24, to expand the College and Community Innovation Program, administered by the Natural Sciences and Engineering Research Council.

Supporting Canadian Leadership in Space

For decades, Canada’s participation in the International Space Station has helped to fuel important scientific advances, and showcased Canada’s ability to create leading-edge space technologies, such as Canadarm2. Canadian space technologies have inspired advances in other fields, such as the NeuroArm, the world’s first robot capable of operating inside an MRI, making previously impossible surgeries possible.

  • Budget 2023 proposes to provide $1.1 billion [emphasis mine] over 14 years, starting in 2023-24, on a cash basis, to the Canadian Space Agency [emphasis mine] to continue Canada’s participation in the International Space Station until 2030.

Looking forward, humanity is returning to the moon [emphasis mine]. Canada intends to join these efforts by contributing a robotic lunar utility vehicle to perform key activities in support of human lunar exploration. Canadian participation in the NASA-led Lunar Gateway station—a space station that will orbit the moon—also presents new opportunities for innovative advances in science and technology. Canada is providing Canadarm3 to the Lunar Gateway, and a Canadian astronaut will join Artemis II, the first crewed mission to the moon since 1972. In Budget 2023, the government is providing further support to assist these missions.

  • Budget 2023 proposes to provide $1.2 billion [emphasis mine] over 13 years, starting in 2024-25, to the Canadian Space Agency to develop and contribute a lunar utility vehicle to assist astronauts on the moon.
  • Budget 2023 proposes to provide $150 million [emphasis mine[ over five years, starting in 2023-24, to the Canadian Space Agency for the next phase of the Lunar Exploration Accelerator Program to support the Canada’s world-class space industry and help accelerate the development of new technologies.
  • Budget 2023 also proposes to provide $76.5 million [emphasis mine] over eight years, starting in 2023-24, on a cash basis, to the Canadian Space Agency in support of Canadian science on the Lunar Gateway station.

Investing in Canada’s Forest Economy

The forestry sector plays an important role in Canada’s natural resource economy [emphasis mine], and is a source of good careers in many rural communities across Canada, including Indigenous communities. As global demand for sustainable forest products grows, continued support for Canada’s forestry sector will help it innovate, grow, and support good middle class jobs for Canadians.

  • Budget 2023 proposes to provide $368.4 million over three years, starting in 2023-24, with $3.1 million in remaining amortization, to Natural Resources Canada to renew and update forest sector support, including for research and development, Indigenous and international leadership, and data. Of this amount, $30.1 million would be sourced from existing departmental resources.

Establishing the Dairy Innovation and Investment Fund

The dairy sector is facing a growing surplus of solids non-fat (SNF) [emphasis mine], a by-product of dairy processing. Limited processing capacity for SNF results in lost opportunities for dairy processors and farmers.

  • Budget 2023 proposes to provide $333 million over ten years, starting in 2023-24, for Agriculture and Agri-Food Canada to support investments in research and development of new products based on SNF, market development for these products, and processing capacity for SNF-based products more broadly.

Supporting Farmers for Diversifying Away from Russian Fertilizers

Russia’s illegal invasion of Ukraine has resulted in higher prices for nitrogen fertilizers, which has had a notable impact on Eastern Canadian farmers who rely heavily on imported fertilizer.

  • Budget 2023 proposes to provide $34.1 million over three years, starting in 2023-24, to Agriculture and Agri-Food Canada’s On-Farm Climate Action Fund to support adoption of nitrogen management practices by Eastern Canadian farmers, that will help optimize the use and reduce the need for fertilizer.

Providing Interest Relief for Agricultural Producers

Farm production costs have increased in Canada and around the world, including as a result Russia’s illegal invasion of Ukraine and global supply chain disruptions. It is important that Canada’s agricultural producers have access to the cash flow they need to cover these costs until they sell their products.

  • Budget 2023 proposes to provide $13 million in 2023-24 to Agriculture and Agri-Food Canada to increase the interest-free limit for loans under the Advance Payments Program from $250,000 to $350,000 for the 2023 program year.

Additionally, the government will consult with provincial and territorial counterparts to explore ways to extend help to small agricultural producers who demonstrate urgent financial need.

Maintaining Livestock Sector Exports with a Foot-and-Mouth Disease Vaccine Bank

Foot-and-Mouth Disease (FMD) is a highly transmissible illness that can affect cattle, pigs, and other cloven-hoofed animals. Recent outbreaks in Asia and Africa have increased the risk of global spread, and a FMD outbreak in Canada would cut off exports for all livestock sectors, with major economic implications. However, the impact of a potential outbreak would be significantly reduced with the early vaccination of livestock. 

  • Budget 2023 proposes to provide $57.5 million over five years, starting in 2023-24, with $5.6 million ongoing, to the Canadian Food Inspection Agency to establish a FMD vaccine bank for Canada, and to develop FMD response plans. The government will seek a cost-sharing arrangement with provinces and territories.

Canadian economic theory (the staples theory), mining, nuclear energy, quantum science, and more

Critical minerals are getting a lot of attention these days. (They were featured in the 2022 budget, see my April 19, 2022 posting, scroll down to the Mining subhead.) This year, US President Joe Biden, in his first visit to Canada as President, singled out critical minerals at the end of his 28 hour state visit (from a March 24, 2023 CBC news online article by Alexander Panetta; Note: Links have been removed),

There was a pot of gold at the end of President Joe Biden’s jaunt to Canada. It’s going to Canada’s mining sector.

The U.S. military will deliver funds this spring to critical minerals projects in both the U.S. and Canada. The goal is to accelerate the development of a critical minerals industry on this continent.

The context is the United States’ intensifying rivalry with China.

The U.S. is desperate to reduce its reliance on its adversary for materials needed to power electric vehicles, electronics and many other products, and has set aside hundreds of millions of dollars under a program called the Defence Production Act.

The Pentagon already has told Canadian companies they would be eligible to apply. It has said the cash would arrive as grants, not loans.

On Friday [March 24, 2023], before Biden left Ottawa, he promised they’ll get some.

The White House and the Prime Minister’s Office announced that companies from both countries will be eligible this spring for money from a $250 million US fund.

Which Canadian companies? The leaders didn’t say. Canadian officials have provided the U.S. with a list of at least 70 projects that could warrant U.S. funding.

“Our nations are blessed with incredible natural resources,” Biden told Canadian parliamentarians during his speech in the House of Commons.

Canada in particular has large quantities of critical minerals [emphasis mine] that are essential for our clean energy future, for the world’s clean energy future.

I don’t believe that Joe Biden has ever heard of the Canadian academic Harold Innis (neither have most Canadians) but Biden is echoing a rather well known theory, in some circles, about Canada’s economy (from the Harold Innis Wikipedia entry),

Harold Adams Innis FRSC (November 5, 1894 – November 9, 1952) was a Canadian professor of political economy at the University of Toronto and the author of seminal works on media, communication theory, and Canadian economic history. He helped develop the staples thesis, which holds that Canada’s culture, political history, and economy have been decisively influenced by the exploitation and export of a series of “staples” such as fur, fish, lumber, wheat, mined metals, and coal. The staple thesis dominated economic history in Canada from the 1930s to 1960s, and continues to be a fundamental part of the Canadian political economic tradition.[8] [all emphases mine]

The staples theory is referred to informally as “hewers of wood and drawers of water.”

Critical Minerals Infrastructure Fund

I cannot find an announcement for this fund (perhaps it’s a US government fund?) but there is a March 7, 2023 Natural Resources Canada news release, Note: A link has been removed,

Simply put, our future depends on critical minerals. The Government of Canada is committed to investing in this future, which is why the Canadian Critical Minerals Strategy — launched by the Honourable Jonathan Wilkinson, Minister of Natural Resources, in December 2022 — is backed by up to $3.8 billion in federal funding. [emphases mine] Today [March 7, 2023], Minister Wilkinson announced more details on the implementation of this Strategy. Over $344 million in funding is supporting the following five new programs and initiatives:

  • Critical Minerals Technology and Innovation Program – $144.4 million for the research, development, demonstration, commercialization and adoption of new technologies and processes that support sustainable growth in Canadian critical minerals value chains and associated innovation ecosystems. 
  • Critical Minerals Geoscience and Data Initiative – $79.2 million to enhance the quality and availability of data and digital technologies to support geoscience and mapping that will accelerate the efficient and effective development of Canadian critical minerals value chains, including by identifying critical minerals reserves and developing pathways for sustainable mineral development. 
  • Global Partnerships Program – $70 million to strengthen Canada’s global leadership role in enhancing critical minerals supply chain resiliency through international collaborations related to critical minerals. 
  • Northern Regulatory Initiative – $40 million to advance Canada’s northern and territorial critical minerals agenda by supporting regulatory dialogue, regional studies, land-use planning, impact assessments and Indigenous consultation.
  • Renewal of the Critical Minerals Centre of Excellence (CMCE) – $10.6 million so the CMCE can continue the ongoing development and implementation of the Canadian Critical Minerals Strategy.

Commentary from the mining community

Mariaan Webb wrote a March 29,2023 article about the budget and the response from the mining community for miningweekly.com, Note: Links have been removed,

The 2023 Budget, delivered by Finance Minister Chrystia Freeland on Tuesday, bolsters the ability of the Canadian mining sector to deliver for the country, recognising the industry’s central role in enabling the transition to a net-zero economy, says Mining Association of Canada (MAC) president and CEO Pierre Gratton.

“Without mining, there are no electric vehicles, no clean power from wind farms, solar panels or nuclear energy, [emphasis mine] and no transmission lines,” said Gratton.

What kind of nuclear energy?

There are two kinds of nuclear energy: fission and fusion. (Fission is the one where the atom is split and requires minerals. Fusion energy is how stars are formed. Much less polluting than fission energy, at this time it is not a commercially viable option nor is it close to being so.)

As far as I’m aware, fusion energy does not require any mined materials. So, Gratton appears to be referring to fission nuclear energy when he’s talking about the mining sector and critical minerals.

I have an October 28, 2022 posting, which provides an overview of fusion energy and the various projects designed to capitalize on it.

Smart Cities in Canada

I was happy to be updated on the Smart Cities Challenge. When I last wrote about it (a March 20, 2018 posting; scroll down to the “Smart Cities, the rest of the country, and Vancouver” subhead). I notice that the successful applicants are from Montreal, Quebec; Guelph, Ontario; communities of Nunavut; and Bridgewater, Nova Scotia. It’s about time northern communities got some attention. It’s hard not to notice that central Canada (i.e., Ontario and Quebec) again dominates.

I look forward to hearing more about the new, upcoming challenge.

The quantum crew

I first made note of what appears to be a fracture in the Canadian quantum community in a May 4, 2021 posting (scroll down to the National Quantum Strategy subhead) about the 2021 budget. I made note of it again in a July 26, 2022 posting (scroll down to the Canadian quantum scene subhead).

In my excerpts from the 3.5 Investing in Tomorrow’s Technology section of the 2023 budget, Xanadu Quantum Technologies, headquartered in Toronto, Ontario is singled out with three other companies (none of which are in the quantum computing field). Oddly, D-Wave Systems (located in British Columbia), which as far as I’m aware is the star of Canada’s quantum computing sector, has yet to be singled out in any budget I’ve seen yet. (I’m estimating I’ve reviewed about 10 budgets.)

Canadians in space

Shortly after the 2023 budget was presented, Canadian astronaut Jeremy Hansen was revealed as one of four astronauts to go on a mission to orbit the moon. From a Canadian Broadcasting (CBC) April 3, 2023 news online article by Nicole Mortillaro (Note: A link has been removed),

Jeremy Hansen is heading to the moon.

The 47-year old Canadian astronaut was announced today as one of four astronauts — along with Christina Koch, Victor Glover and Reid Wiseman — who will be part of NASA’s [US National Aeronautics and Space Administration] Artemis II mission.

Hansen was one of four active Canadian astronauts that included Jennifer Sidey-Gibbons, Joshua Kutryk and David Saint-Jacques vying for a seat on the Orion spacecraft set to orbit the moon.

Artemis II is the second step in NASA’s mission to return astronauts to the surface of the moon. 

The astronauts won’t be landing, but rather they will orbit for 10 days in the Orion spacecraft, testing key components to prepare for Artemis III that will place humans back on the moon some time in 2025 for the first time since 1972.

Canada gets a seat on Artemis II due to its contributions to Lunar Gateway, a space station that will orbit the moon. But Canada is also building a lunar rover provided by Canadensys Aerospace.

On Monday [April 3, 2023], Hansen noted there are two reasons a Canadian is going to the moon, adding that it “makes me smile when I say that.”

The first, he said, is American leadership, and the decision to curate an international team.

“The second reason is Canada’s can-do attitude,” he said proudly.

In addition to our ‘can-do attitude,” we’re also spending some big money, i.e., the Canadian government has proposed in its 2023 budget some $2.5B to various space and lunar efforts over the next several years.

Chapter 3 odds and sods

First seen in the 2022 budget, the patent box regime makes a second appearance in the 2023 budget where apparently ‘stakeholders will be engaged’ later this year. At least, they’re not rushing into this. (For the original announcement and an explanation of a patent box regime, see my April 19, 2022 budget review; scroll down to the Review of Tax Support to R&D and Intellectual Property subhead.)

I’m happy to see the Dairy Innovation and Investment Fund. I’m particularly happy to see a focus on finding uses for solids non-fat (SNF) by providing “$333 million over ten years, starting in 2023-24, … research and development of new products based on SNF [emphasis mine], market development for these products, and processing capacity for SNF-based products more broadly.”

This investment contrasts with the approach to cellulose nanocrystals (CNC) derived from wood (i.e., the forest economy), where the Canadian government invested heavily in research and even opened a production facility under the auspices of a company, CelluForce. It was a little problematic.

By 2013, the facility had a stockpile of CNC and nowhere to sell it. That’s right, no market for CNC as there had been no product development. (See my May 8, 2012 posting where that lack is mentioned, specifically there’s a quote from Tim Harper in an excerpted Globe and Mail article. My August 17, 2016 posting notes that the stockpile was diminishing. The CelluForce website makes no mention of it now in 2023.)

It’s good to see the government emphasis on research into developing products for SNFs especially after the CelluForce stockpile and in light of US President Joe Biden’s recent enthusiasm over our critical minerals.

Chapter 4: Advancing Reconciliation and Building a Canada That Works for Everyone

Chapter 4: Advancing Reconciliation and Building a Canada That Works for Everyone offers this, from https://www.budget.canada.ca/2023/report-rapport/toc-tdm-en.html,

4.3 Clean Air and Clean Water

Progress on Biodiversity

Montreal recently hosted the Fifteenth Conference of the Parties (COP15) to the United Nations Convention on Biological Diversity, which led to a new Post-2020 Global Biodiversity Framework. During COP15, Canada announced new funding for biodiversity and conservation measures at home and abroad that will support the implementation of the Global Biodiversity Framework, including $800 million to support Indigenous-led conservation within Canada through the innovative Project Finance for Permanence model.

Protecting Our Freshwater

Canada is home to 20 per cent of the world’s freshwater supply. Healthy lakes and rivers are essential to Canadians, communities, and businesses across the country. Recognizing the threat to freshwater caused by climate change and pollution, the federal government is moving forward to establish a new Canada Water Agency and make major investments in a strengthened Freshwater Action Plan.

  • Budget 2023 proposes to provide $650 million over ten years, starting in 2023-24, to support monitoring, assessment, and restoration work in the Great Lakes, Lake Winnipeg, Lake of the Woods, St. Lawrence River, Fraser River, Saint John River, Mackenzie River, and Lake Simcoe. Budget 2023 also proposes to provide $22.6 million over three years, starting in 2023-24, to support better coordination of efforts to protect freshwater across Canada.
  • Budget 2023 also proposes to provide $85.1 million over five years, starting in 2023-24, with $0.4 million in remaining amortization and $21 million ongoing thereafter to support the creation of the Canada Water Agency [emphasis mine], which will be headquartered in Winnipeg. By the end of 2023, the government will introduce legislation that will fully establish the Canada Water Agency as a standalone entity.

Cleaner and Healthier Ports

Canada’s ports are at the heart of our supply chains, delivering goods to Canadians and allowing our businesses to reach global markets. As rising shipping levels enable and create economic growth and good jobs, the federal government is taking action to protect Canada’s coastal ecosystems and communities.

  • Budget 2023 proposes to provide $165.4 million over seven years, starting in 2023-24, to Transport Canada to establish a Green Shipping Corridor Program to reduce the impact of marine shipping on surrounding communities and ecosystems. The program will help spur the launch of the next generation of clean ships, invest in shore power technology, and prioritize low-emission and low-noise vessels at ports.

Water, water everywhere

I wasn’t expecting to find mention of establishing a Canada Water Agency and details are sketchy other than, It will be in Winnipeg, Manitoba and there will be government funding. Fingers crossed that this agency will do some good work (whatever that might be). Personally, I’d like to see some action with regard to droughts.

In British Columbia (BC) where I live and which most of us think of as ‘water rich’, is suffering under conditions such that our rivers and lakes are at very low levels according to an April 6, 2023 article by Glenda Luymes for the Vancouver Sun (print version, p. A4),

On the North American WaterWatch map, which codes river flows using a series of coloured dots, high flows are represented in various shades of blue while low flows are represented in red hues. On Wednesday [April 5, 2023], most of BC was speckled red, brown and orange, with the majority of the province’s rivers flowing “much below normal.”

“It does not bode well for the fish populations,” said Marvin Rosenau, a fisheries and ecosystems instructor at BCIT [British Columbia Institute of Technology]. …

Rosenau said low water last fall [2022], when much of BC was in the grip of drought, decreased salmon habitat during spawning season. …

BC has already seen small early season wildfires, including one near Merritt last weekend [April 1/2, 2023]. …

Getting back to the Canada Water Agency, there’s this March 29, 2023 CBC news online article by Bartley Kives,

The 2023 federal budget calls for a new national water agency to be based in Winnipeg, provided Justin Trudeau’s Liberal government remains in power long enough to see it established [emphasis mine] in the Manitoba capital.

The budget announced on Tuesday [March 28, 2023] calls for the creation of the Canada Water Agency, a new federal entity with a headquarters in Winnipeg.

While the federal government is still determining precisely what the new agency will do, one Winnipeg-based environmental organization expects it to become a one-stop shop for water science, water quality assessment and water management [emphasis mine].

“This is something that we don’t actually have in this country at the moment,” said Matt McCandless, a vice-president for the non-profit International Institute for Sustainable Development.

Right now, municipalities, provinces and Indigenous authorities take different approaches to managing water quality, water science, flooding and droughts, said McCandless, adding a national water agency could provide more co-ordination.

For now, it’s unknown how many employees will be based at the Canada Water Agency’s Winnipeg headquarters. According to the budget, legislation to create the agency won’t be introduced until later this year [emphasis mine].

That means the Winnipeg headquarters likely won’t materialize before 2024, one year before the Trudeau minority government faces re-election, assuming it doesn’t lose the confidence of the House of Commons beforehand [emphasis mine].

Nonetheless, several Canadian cities and provinces were vying for the Canada Water Agency’s headquarters, including Manitoba.

The budget also calls for $65 million worth of annual spending on lake science and restoration, with an unstated fraction of that cash devoted to Lake Winnipeg.

McCandless calls the spending on water science an improvement over previous budgets.

Kives seems a tad jaundiced but you get that way (confession: I have too) when covering government spending promises.

Part 2 (military spending and general comments) will be posted sometime during the week of April 24-28, 2023.

Who’s running the life science companies’ public relations campaign in British Columbia (Vancouver, Canada)?

I started writing this in the aftermath of the 2021 Canadian federal budget when most of the action (so far) occurred but if you keep going to the end of this post you’ll find updates for Precision Nanosystems and AcCellera and a few extra bits. Also, you may want to check out my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan and some of the ‘rough and tumble’ of the biotechnology scene in BC/Canada. Now, onto my analysis of the life sciences public relations campaign in British Columbia.

Gordon Hoekstra’s May 7, 2021 article (also in print on May 8, 2021) about the British Columbia (mostly in Vancouver) biotechnology scene in the Vancouver Sun is the starting point for this story.

His entry (whether the reporter realizes it or not) into a communications (or public relations) campaign spanning federal, provincial, and municipal jurisdictions is well written and quite informative. While it’s tempting to attribute the whole thing to a single evil genius or mastermind in answer to the question posed in the head, the ‘campaign’ is likely a targeted effort by one or more groups and individuals enhanced with a little luck.

Federal and provincial money for life sciences and technology

The Business Council of British Columbia’s April 22, 2021 Federal & B.C. Budgets 2021 Analysis (PDF), notes this in its Highlights section,

•Another priority reflected in both budgets is boosting innovation and accelerating the growth of technology-producing companies. The federal budget [April 19, 2021] is spending billions more to support the life sciences and bio-manufacturing industry, clean technologies, the development of electric vehicles, the aerospace sector, quantum computing, AI, genomics, and digital technologies, among others.

•B.C.’s budget [April 20, 2021] also provides funding to spur innovation, support the technology sector and grow locally-based companies. In this area the main item is the new InBC Investment Corporation [emphasis mine], first announced last summer. Endowed with $500 million financed via an agency loan, the Corporation will establish a fund to invest in growing and “anchoring” high-growth [emphasis mine] B.C. businesses.

Their in-depth analysis does not provide more detail about the life sciences investments in the 2021 Canadian federal budget or the 2021 BC provincial budget.

My May 4, 2021 posting details many of the Canadian federal investments in life sciences and other technology areas of interest. The 2021 BC budget announcement is so vague, it didn’t merit much more than this mention until now.

InBC Investment Corporation (BC’s contribution)

InBC Investment Corporation was set up on or about April 27, 2021 as three news ‘references’ (brief summaries with a link) suggest: InBC Investment Corp. Act, InBC Announcement, $500-million investment fund paves way for StrongerBC.

While the corporation does not have a specific mandate to fund the biotechnology sector, given the current enthusiasm, it’s easy to believe they might be more inclined to fund them than not, regardless of any expertise they or may not have specifically in that field.

Of most interest to me was InBC’s Board of Directors, which I tracked down to a BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release,

InBC Investment Corp. now has a full board of directors with backgrounds in finance, economics, impact investing and business to provide strategic guidance and accountability for the new Crown corporation.

InBC will support startups [emphasis mine], help promising companies scale up and work with a “triple bottom line” mandate that considers people, the planet and profits, to position British Columbia as a front-runner in the post-pandemic economy.

Christine Bergeron, president and chief executive officer of Vancity, will serve as the new board chair of InBC Investment Corp. The nine-member board of directors is made up of both public and private sector members who are responsible for oversight of the corporation, including its mission, policies and goals.

The InBC board members were selected through a comprehensive process, guided by the principles of the Crown Agencies and Board Resourcing Office. Candidates with a variety of relevant backgrounds were considered to form a strong board consisting of seven women and two men. The members appointed represent diversity as well as appropriate areas of expertise.

The following people were selected as members on the board of directors:

  • Christine Bergeron, president and CEO, Vancity
  • Kevin Campbell, managing director of investment banking, board of directors, Haywood Securities
  • Ingrid Leong, VP finance for JH Investments and chief investment officer, Houssian Foundation
  • Glen Lougheed, serial tech entrepreneur and angel investor
  • Suzanne Trottier, vice-president of Indigenous trust services, First Nations Bank Trust
  • Carole James, former minister of finance and deputy premier, Government of British Columbia
  • Iglika Ivanova, senior economist, public interest researcher, BC Office of the Canadian Centre for Policy Alternatives
  • Bobbi Plecas, deputy minister, B.C.’s Ministry of Jobs, Economic Recovery and Innovation
  • Heather Wood, deputy minister, B.C.’s Ministry of Finance

Legislation to provide the governance framework for InBC was introduced by the legislative assembly on April 27, 2021.

Board experience at growing a startup?

This group of people doesn’t seem to have a shred of experience with startups. Glen Lougheed’s “serial tech entrepreneur and angel investor” description means nothing to me and the description he provides in his LinkedIn profile doesn’t clear up matters,

I am a product and business development professional with an entrepreneurial attitude and strong technical skills. I have been building companies both mine and others since I was a teenager.

Having looked up the two companies for which he is currently acting as Chief Executive Officer, Lougheed’s interest appears to be focused on the use of ‘big data’ in marketing and communications campaigns.

Perhaps startup experience isn’t necessary since the board has been appointed to do this (from the BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release; click on the Backgrounder),

Responsibilities of the InBC Investment Corp. board of directors

The board of directors will be responsible for oversight of the management of the affairs of the corporation. This includes:

  • selecting and approving the chief executive officer and chief innovation officer and monitoring performance and accountabilities;
  • reviewing and approving annual corporate financial statements;
  • oversight of policies that relate to InBC’s mandate and holding the executive to account for its accountabilities with respect to InBC’s mandate;
  • oversight of InBC’s operations; and
  • selection and appointment of InBC’s auditor.

Relationships

So, we have two government civil servants, Wood (Deputy Minister of B.C.’s Ministry of Finance) and Plecas (Deputy Minister of B.C.’s Ministry of Jobs, Economic Recovery and Innovation), and James, a BC Minister of Finance, who left the job several months ago. Then we have Lougheed, recently resigned (May 2021) as special advisor on innovation and technology to the BC Minister of Jobs, Economic Recovery and Innovation.

It would seem almost half of this new board is or has been affiliated with the government and, likely, know each other.

I expect there are more relationships to be found but my interest is in the overall picture as it pertains to the biotechnology scene. This board (except possibly for Lougheed) does not seem to have any experience in the biotechnology sector or growing any sort of startup business in any technology field.

Presumably, the new chief executive officer (CEO) and new chief innovation officer (CIO) will have some of the necessary experience. Still, biotechnology isn’t the same as digital technology, an area where the BC technology community is quite strong. (The Canadian federal government’s Digital Technology Supercluster is headquartered in BC.)

I imagine the politics around who gets hired as CEO and as CIO will be quite interesting.

See the ‘Updates and extras’ at the end of this posting for more mention of this ‘secretive’ government corporation.

The BC biotech gorillas

AbCellera was BC’s biggest biotech story in 2020/21 (see my Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist post from December 30, 2020 for more. Do check out the subsection titled “Avo Media …” for a look at an unexpectedly interlaced relationship). Note: The AbCellera COVID-19 treatment is not a vaccine or a vaccine delivery system.

It was a bit surprising that Acuitas Therapeutics didn’t get more attention although Hoekstra seems to have addressed that shortcoming in his May 7, 2021 article by using Thomas Madden and Acuitas as the hook for the story,

By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China.

The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been more than 400 deaths and more than 20,000 cases, most of those in China.

But the virus was spreading around the world. Deaths had occurred in Hong Kong and the Philippines, and the virus had been detected in the U.S. and Canada.

By early January of 2020, scientists in China had already sequenced the virus’s genome and made it public, allowing scientists to begin the research for a vaccine.

Scientists expected that could take years.

But, as a second case was confirmed in B.C. in early February, Thomas Madden, a world-renowned expert in nanotechnology who heads Vancouver-based biotech company Acuitas Therapeutics, flew to Germany. [emphases mine]

Acuitas was in the business of creating lipid nanoparticles, microscopic biological vehicles that could deliver drugs [emphasis mine] — for example, to specifically target cancers in the body.

Scientists are already beginning to say it’s likely that a booster vaccine will be needed [emphasis mine] next year to deal with the virus variants.

Madden, the head of Acuitas, says it makes absolute sense to use the new biotechnology, for example, the use of messenger RNA vaccines, to prepare and fight future pandemics.

Says Madden [emphasis mine]: “The technology in terms of what it’s able to do is absolutely phenomenal. It’s just taken us 40 years to get here.”

So, Hoekstra reminds us of the international nature and urgency of the crisis, then, introduces Acuitas as a vital and local player in solutions deployed internationally, and, finally, brings us back to Acuitas after providing an overview of the BC biotech scene and the federal and provincial government’s latest moves,

AbCellera Biologics is more of a supporting player, along with a number of other companies, in Hoekstra’s story,

Sandwiched in the middle, you’ll find what I think is the point of the story,

LifeSciences BC and the provincial government’s commitments

From Hoekstra’s May 7, 2021 article,

The importance of the biotech sector in providing protection against pandemics has caught the attention of the federal and B.C. governments. It has also been noticed by the private markets.

In its budget [April 19, 2021] earlier this month [sic], the federal government promised more than $2 billion in the next seven years to support “promising” life sciences and bio-manufacturing firms, research, training, education and vaccine candidates.

Some companies, including Precision NanoSystems, have already got federal funding. The Vancouver company received $18.2 million last year to help develop its self-replicating mRNA vaccine and another $25 million in early 2021 to assist building a $50-million facility to produce the vaccine.

Last fall, Symvivo received $2.8 million from the National Research Council to help develop its oral COVID-19 vaccine.

AbCellera has also received a pledge of $175.6 million to help build an accredited manufacturing facility in Vancouver [emphasis mine] to produce antibody treatments.

AbCellera expects to double its 230-person workforce over the next two years as it expands its Vancouver campus.

When AbCellera became a publicly traded company late last year, it raised more than $500 million and had a recent market capitalization, the value of its stock, of about $8.5 billion.

When the B.C. government delivered its throne speech recently, the contribution of the province’s life sciences sector in the fight against the COVID-19 pandemic was highlighted, with Precision NanoSystems, AbCellera and StarFish Medical getting mentions. “Their work will not only help bring us out of the pandemic, it will position our province for success in the years ahead,” said B.C.’s Lt. Gov. Jane Austen in delivering the throne speech.

When the budget was released the following week [April 20, 2021], B.C. Finance Minister Selina Robinson said a new three-year, $500-million strategic investment fund would help support and scale up tech firms.

Despite their successes, B.C. biotech firms have faced challenges.

SaNOtize had to go to the U.K. to get support for clinical trials and AbCellera has been disappointed that despite Health Canada emergency approval of its COVID-19 treatment, provinces have been reluctant to use Bamlanivimab.

Hansen, AbCellera’s CEO and a former University of B.C. professor with a PhD in applied physics and biotechnology, said he believes that biotech is the most important frontier of technology.

In the past, while great science was launched from B.C.’s universities, not as great a job was done on turning that science into innovation, jobs [emphasis mine] and the capacity to bring new products to market, possibly because of a lack of entrepreneurship and polices to make it more attractive to companies to grow and thrive here and move here, notes Hansen.

Hurlburt [Wendy Hurlburt], the LifeSciences B.C. CEO, says that policies, including tax structure and patenting [emphasis mine], that encourages innovation companies are needed to support the biotech sector.

But, adds Hansen: “Here in Vancouver, I feel like we’re turning the corner. There’s probably never been a time when Vancouver’s biotech sector [emphasis mine] was stronger. And the future looks very good.”

Not only is the province involved but so is the City of Vancouver (more about that in a bit).

It’s not all about the cash

Hoekstra’s May 7, 2021 article helped answer a question I had in the title of another posting, January 22, 2021: Why is Precision Nanosystems Inc. in the local (Vancouver, Canada) newspaper? (See the ‘Updates and extras’ at the end of this posting for more to the answer.)

This campaign has been building for a while. In the “Is it magic or how does the federal budget get developed? subsection of my May 4, 2021 posting on the 2021 Canadian federal budget I speculated a little bit,

I believe most of the priorities are set by power players behind the scenes. We glimpsed some of the dynamics courtesy of the WE Charity scandal 2020/21 and the SNC-Lavalin scandal in 2019.

Access to special meetings and encounters are not likely to be given to any member of the ‘great unwashed’ but we do get to see the briefs that are submitted in anticipation of a new budget. These briefs and meetings with witnesses are available on the Parliament of Canada website (Standing Committee on Finance (FINA) webpage for pre-budget consultations.

AbCellera submitted a brief dated August 7, 2020 (PDF) detailing how they would like to see the Income Tax Act amended. It’s not always about getting cash, although that’s very important. In this brief, the company wants “… improved access to the enhanced Scientific Research & Experimental Development tax credit.”

There are many aspects to these campaigns including the federal Income Tax Act and, in this case, municipal involvement.

Vancouver (city government) and the biotech sector

About five weeks prior to the 2021 Canadian federal budget and BC provincial budget announcements, there was some news from the City of Vancouver (from a March 10, 2021 article by Kenneth Chan for dailyhive.com), Note: Links have been removed,

Major expansion plans are abound for AbCellera over the next few years to the extent that the Vancouver-based biotechnology company is now looking to build a massive purpose-built office and medical laboratory campus in Mount Pleasant (Vancouver neighbourhood).

It would be a redevelopment of the entire city block …

… earlier today, Vancouver City Council unanimously approved a rezoning enquiry allowing city staff to work with the proponent and accept a formal application for review.

This special additional pre-application step is required due to the temporary ban [emphasis mine] on most types of rezonings within the Broadway Plan’s planning area, until the plan is finalized at the end of 2021.

But city staff are willing to make this a rare exception due to the economic opportunity [emphasis mine] presented by the proposal and the healthcare-related aspects.

“The reasons for advancing this quickly are they are rapidly growing and would like to stay in Vancouver, and we would like them to… We’re very glad to have this company in Vancouver and want to provide them with a permanent home, but in order to scale up, the timeframe to produce their therapy [for viruses] is really time sensitive,” Gil Kelley, the chief urban planner of the City of Vancouver, told city council during today’s [March 10, 2021] meeting.

….

Roughly 10 days after the 2021 budgets are announced, there’s this from Kenneth Chan’s April 29,2021 article on dailyhive.com,

Plans for AbCellera Biologics’ major footprint expansion in Vancouver’s Mount Pleasant Industrial Area are moving forward quickly.

Based on the application submitted this week, the Vancouver-based biotechnology company is proposing to redevelop 110 West 4th Avenue …

It will be designated as the rapidly growing company’s global headquarters.

… city staff are providing AbCellera with the highly rare, expedited stream of combining the rezoning and development application processes into one.

By the middle of this decade, AbCellera will have four locations in the area, including its current 21,000 sq ft office at 2215 Yukon Street and a new 44,000 sq ft office nearing completion at 2131 Manitoba Street, just south of its future main hub.

“We’re building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world,” said Carl Hansen, CEO and president of AbCellera, in a statement.

AbCellera has gained significant international attention over the past year after it co-developed the first authorized COVID-19 antibody therapy for emergency use in high-risk patients in Canada and the United States.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO [initial public offering] by a Canadian biotech company.

“We see this new site as a creative hub for engineers, software developers, data scientists, biologists and bioinformaticians to collaborate, innovate, and push the frontiers of technology.” [said Veronique Lecault, the COO of AbCellera]

Additionally, AbCellera is also planning to build a clinical-grade, antibody manufacturing facility in Metro Vancouver, funded in part by the $176-million investment it received from the federal government in Spring 2020 [see May 3, 2020 AbCellera news release].

Not cash but AbCellera did get an expedited process for rezoning and I imagine there will be more special treatment as this progresses. (See the ‘Updates and extras’ at the end of this posting for news about the expedited process.)

It’s likely there are other companies in the BC’s life science sector that are eyeing this development with great interest and high hopes for themselves.

What it takes

COVID-19 seems to have galvanized interest and support almost everywhere in the world for life sciences.

I don’t believe that anyone in the life sciences planned for or rejoiced at news of this pandemic. However, the Canadian biotech sector has been working for decades to establish itself as an important economic resource. and, sadly, COVID-19 has been a timely development.

All those years of lobbying, also known as, government relations, marketing, investor relations, public relations and more served as preparation for what looks like a concerted effort and it has paid off in BC at the federal level, provincial level, and municipal level (at least one).

The campaigns continue. Here’s Wendy Hurlburt, president and CEO of LifeSciences BC in a May 14, 2021 Conversations That Matter Vancouver Sun podcast with Stuart McNish. Note: Hurlburt makes an odd comment at about the 7 min. 30 secs. mark regarding insulin and patents.

Her dismay over lost opportunities regarding the insulin patent is right in line with Canada’s current patent mania. See my May 13, 2021 posting, Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines. As far as I’m aware, Canada’s stance has not changed. Interestingly, Hoekstra’s article doesn’t mention COVID-19 patent waivers.

By contrast, here’s what Frederick Banting (one of the discoverers) had to say about his patent, (from the Banting House Insulin Patents webpage),

About the sale of the patent of insulin for $1 Banting reportedly said, “Insulin belongs to the world, not to me.”

… On January 23rd, 1923 Banting, [Charles] Best, and [James] Collip were awarded the American patents for insulin which they sold to the University of Toronto for $1.00 each.

Hurlburt goes on to express dismay over taxes and notes that some companies may leave for other jurisdictions, which means we will lose ‘innovation’. This is a very common ploy coming from any of the technology sectors and can be dated back at least 30 years.

Unmentioned is the dream/business model that so many Canadian tech entrepreneurs have: grow the company, sell it for a lot of money, and retire, preferably before the age of 40.

Getting back to my point, the current situation is not attributable to one individual or to one company’s efforts or to one life science nonprofit or to one federal Network Centre for Excellence (NanoMedicines Innovation Network [NMIN] located at the University of British Columbia).

Note: I have more about the NMIN and Acuitas Therapeutics in a November 12, 2021 posting and there’s more about NMIN’s 7th annual conference and a very high profile guest in a September 11, 2020 posting.

Strategy at the federal, provincial, and local governments, with an eye to the international scene, has been augmented by luck and opportunism.

Updates and extras

Where updates are concerned I have one for Precision Nanosystems and one for AbCellera. I have extras with regard to Moderna and Canada and, BC’s special fund, inBC Investment Corporation. For anyone who’s curious about Banting and the high cost of insulin, I have a couple of links to further reading.

Precision Nanosystems

From an August 11, 2021 article by Kenneth Chan (Note: Links have been removed),

A homegrown pharmaceutical company has announced plans to significantly scale its operations with the opening of a new production facility in Vancouver’s False Creek Flats.

The new Evolution Block building will contain PNI’s new global headquarters and a new genetic medicine Good Manufacturing Practice (GMP) biomanufacturing centre, which would allow the company to expand its capabilities to include the clinical manufacturing of RNA vaccines and therapeutics.

Federal funding totalling $25.1 million for PNI was first announced in February 2021 towards covering part of the development costs of such a facility, as part of the federal government’s new strategy to better ensure Canada has the domestic capacity to secure its own COVID-19 vaccines and prepare the country for future pandemics. It is estimated the vaccine production capacity of the new facility will be 240 million doses annually.

PNI’s location in the False Creek Flats is strategic, given the close proximity to the new St. Paul’s Hospital campus and the growing concentration of tech and healthcare-based industrial businesses.

AbCellera

From a June 22, 2021 article by Kenneth Chan (Note: Links have been removed),

The rapidly growing Vancouver-based biotechnology company announced this morning their 130,000 sq ft Good Manufacturing Practices (GMP) facility will be located on a two-acre site at the 900 block of Evans Avenue, replacing the Urban Beach volleyball courts just next to the City of Vancouver’s Evans maintenance centre and the Regional Recycling Vancouver Bottle Depot.

GMP is partially funded by the $175 million in federal funding received by the company last year to support research into coronavirus treatment.

GMP adds to AbCellera’s major plans to build a new headquarters in close proximity at 110-150 West 4th Avenue in the Mount Pleasant Industrial Area — a city block-sized campus with a total of 380,000 sq ft of laboratory and office space for research and corporate uses.

Both campus buildings are being reviewed under the City of Vancouver’s rare streamlined, expedited process [emphasis mine] of combining the rezoning and development permit applications. AbCellera formally announced its campus plans in April 2021.

AbCellera gained significant international attention last year when it developed the world’s first monoclonal antibody therapy for COVID-19 to be authorized for emergency use in high-risk patients in Canada and the United States. According to the company, over 400,000 doses of its bamlanivimab drug have been administered around the world, and it is estimated to have kept more than 22,000 people out of hospital — saving at least 11,000 lives.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO by a Canadian biotech company.

Moderna and Canada

It seems like yesterday that Derek Rossi (co-founder of Moderna) was talking about Canada’s need for a biotechnology hub. (see this June 17, 2021 article by Barbara Shecter for the Financial Post). Interestingly, there’s been an announcement of a memorandum of understanding (these things are announced all the time and don’t necessarily result in anything) between Moderna and the government of Canada according to an August 10, 2021 item on the Canadian Broadcasting Corporation (CBC) news website,

Massachusetts-based drug maker Moderna will build an mRNA vaccine manufacturing plant in Canada within the next two years, CEO Stephane Bancel said Tuesday [August 10, 2021; Note the timing, the writ for the next federal election was dropped on August 15, 2021].

The company has signed a memorandum of understanding with the federal government that will result in Canada becoming the home of Moderna’s first foreign operation. It’s not clear yet how much money Canada has offered to Moderna [emphasis mine] for the project.

Canada, whose life sciences industry has been decimated over the last three decades, wants in on the action. Prime Minister Justin Trudeau has promised to rebuild the industry, and the recent budget included a $2.2 billion, seven-year investment to grow the life science and biotech sectors.

Almost half of that targets companies that want to expand or set up vaccine and drug production in Canada. None of the COVID-19 vaccines to date have been made in Canada, leaving the country entirely reliant on imports to fill vaccine orders. As a result, Canada was slower out of the gate on immunizations than some of its counterparts with domestic production, and likely had to pay more per dose for some vaccines as well.

The location of the new facility hasn’t been finalized, but Bancel said the availability of an educated workforce will be the main deciding factor. He said the design is done and they’ll need to start hiring very soon so training can begin.

it’s not exactly a hub but who knows what the future will bring? I imagine there’s going to be some serious wrangling behind the scenes as the provinces battle to be the location for the facility. Note that Innovation Minister François-Philippe Champagne who made the announcement with Bancel in Montréal represents a federal riding in Québec. (BTW, Bancel is from France and seems to have spent much of his adult life in the US.) Of course anything can happen and I’m sure the BC contingent will make themselves felt but it would seem that Quebec is the front runner for now, assuming this memorandum of understanding leads to a facility. Given that we are in the midst of a federal election, it seems more probable than it might otherwise.

inBC Investment Corporation

Bob Mackin’s August 13, 2021 article for theBreaker.news sheds some light on how that corporation was formed so very quickly and more,

The B.C. NDP government rejigged the B.C. Immigrant Investor Fund last year, but refused to release the business case when it was rebranded as inBC Investment Corp. in late April [2021].

theBreaker.news requested the business case for the $500 million fund, which is overseen by a board of NDP patronage appointees, on May 6 [2021].

The 123-page document below is heavily censored — meaning the NDP cabinet is refusing to tell British Columbians the projected operating costs (including board expenses, salary and benefits, office space, operating and administration), full-time equivalents, and cash flows for the newest Crown corporation. inBC bills itself as a triple-bottom line organization, meaning it intends to invest on the basis of social, environmental and economic values.

When its enabling legislation was tabled, the NDP took steps to exempt inBC from the freedom of information law.

Thank you, Mr. Mackin.

More on Banting, insulin and patents

Caitlyn McClure’s 2016 article (Insulin’s Inventor Sold the Patent for $1. Then Drug Companies Got Hold of It.) for other98.com is a brief and pithy explanation for why insulin costs so much. Alanna Mitchell’s August 13, 2019 article for Maclean’s magazine investigates ‘insulin tourism’ and offers more detail as to how this situation has come about.

One last reminder, my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan provides insight into how competitive and rough the bitotechnology scene can be here in BC/Canada.

Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines

At about 7:15 am PT this morning , May 13, 2021, I saw Dr. Mona Nemer’s (Canada’s Chief Science Advisor) tweet (Note: I’m sorry the formatting isn’t better,

Maryse de la Giroday@frogheart Does this mean Canada will support a waiver on patent rights for COVID-19 vaccines?

7:18 AM · May 13, 2021

Dr. Mona Nemer@ChiefSciCanThe global health crisis of the past year has underscored the critical importance of openly sharing scientific information. We are one step closer to making #openscience a reality around the world. So pleased that my office was part of these discussions. http://webcast.unesco.org/events/2021-05-OS-IGM/ Quote Tweet

Canada at UNESCO@Canada2UNESCO · May 6@Canada2UNESCO is partaking in negotiations today on the draft recommendation on #OpenScience The benefits of #science and #technology to health, the #economy and #development should be available to all.6:40 AM · May 13, 2021·Twitter Web App

No reply. No surprise

Brief summary of Canada’s COVID-19 patent rights nonwaiver

You’ll find more about the UNESCO meeting on open science in last week’s May 7, 2021 posting (Listen in on a UNESCO (United Nations Educational, Scientific and Cultural Organization) meeting [about Open Science]).

At the time, I noted a disparity in Canada’s policies centering on open science and patents; scroll down to the “Comments on open science and intellectual property in Canada” subsection for a more nuanced analysis. For those who don’t have the patience and/or the time, it boils down to this:

  1. Canada is happily participating in a UNESCO meeting on open science,
  2. the 2021 Canadian federal budget just dedicated a big chunk of money to augmenting Canada’s national patent strategy, and
  3. Canada is “willing to discuss” a waiver at the World Trade Organization (WTO) meetings.

I predicted UNESCO would see our representative’s enthusiastic participation while our representative at the WTO meeting would dance around the topic without committing. to anything. Sadly, it’s starting to look like I was right.

Leigh Beadon in a May 12, 2021 posting on Techdirt reveals the situation is worse than I thought (Note: Links have been removed),

Few things illustrate the broken state of our global intellectual property system better than the fact that, well over a year into this devastating pandemic and in the face of a strong IP waiver push by some of the hardest hit countries, patents are still holding back the production of life-saving vaccines. And of all the countries opposing a waiver at the WTO (or withholding support for it, which is functionally the same thing), Canada might be the most frustrating [emphasis mine].

Canada is the biggest hoarder [emphasis mine] of vaccine pre-orders, having secured enough to vaccinate the population five times over. Despite this, it has constantly run into supply problems and lagged behind comparable countries when it comes to administering the vaccines on a per capita basis. In response to criticism of its hoarding, the government continues to focus on its plans to donate all surplus doses to the COVAX vaccine sharing program — but these promises were somewhat more convincing before Canada became the only G7 country to withdraw doses from COVAX. Despite all this, and despite pressure from experts who explain how vaccine hoarding will prolong the pandemic for everyone, the country has continually refused to voice its support for a TRIPS patent waiver at the WTO.

Momentum for changing Canada’s position on a COVID-19 vaccine patent right waivers?

Maclean’s magazine has a May 10, 2021 open letter to Prime Minister Justin Trudeau,

Dear Prime Minister Trudeau,

The only way to combat this pandemic successfully is through a massive global vaccination campaign on a scale and timeline never before undertaken. This requires the production of effective tools and technologies to fight COVID-19 at scale and coordinated global distribution efforts.

The Trade-Related Aspect of Intellectual Property Rights (TRIPS) agreement at the World Trade Organization (WTO) is leading to the opposite outcome. Vaccine production is hindered by granting pharmaceutical companies monopoly power through protection of intellectual property rights, industrial designs and trade secrets. Pharmaceutical companies’ refusal to engage in health technology knowledge transfer makes large-scale, global vaccine production in (and for) low- and middle-income countries all but impossible. The current distribution of vaccines globally speaks to these obstacles.

Hundreds of civil society groups, the World Health Organization (WHO), and the elected governments of over 100 countries, including India, Afghanistan, Bangladesh, Nepal, Pakistan and Sri Lanka have come together and stated that current intellectual property protections reduce the availability of vaccines for protecting their people. On May 5, 2021 the United States also announced its intention to support a temporary waiver for vaccines at the WTO.

We are writing to ask our Canadian government to demonstrate its commitment to an equitable global pandemic response by supporting a temporary waiver of the TRIPS agreement. But clearly that is a necessary but not a sufficient first step. We recognize that scaling up vaccine production requires more than just a waiver of intellectual property rights, so we further request that our government support the WHO’s COVID-19 Technology Access Pool (C-TAP) to facilitate knowledge sharing and work with the WTO to address the supply chain and export constraints currently impeding vaccine production. Finally, because vaccines must be rolled out as part of an integrated strategy to end the acute phase of the epidemic, we request that Canada support the full scope of the TRIPS waiver, which extends to all essential COVID-19 products and technologies, including vaccines, diagnostics and therapeutics.

The status quo is clearly not working fast enough to end the acute phase of the pandemic globally. This waiver respects global intellectual property frameworks and takes advantage of existing provisions for exceptions during emergencies, as enshrined in the TRIPS agreement. Empowering countries to take measures to protect their own people is fundamental to bringing this pandemic to an end.

Anand Giridharadas (author of the 2018 book, Winners Take All: The Elite Charade of Changing the World) also makes the case for a patent rights waiver in his May 11, 2021 posting on The Ink, Note: A link has been removed,

Patents are temporary monopolies granted to inventors, to reward invention and thus encourage more of it. But what happens when you invent a drug that people around the world require to stay alive? What happens when, furthermore, that drug was built in part on technology the public paid for? Are there limits to intellectual property?

For years, activists have pressured the United States government to break or suspend patents in particular cases, as with HIV/Aids. They have had little luck. Indeed, the United States has often fought developing countries when they try to break patents to do right by their citizens, choosing American drug companies over dying people.

So it was a dramatic swerve when, last week, the Biden administration announced that it supported a waiver of the patents for Covid vaccines.

Not long afterward, I reached out to several leading activists for vaccine access to understand the significance of the announcement and where we go from here.

in all this talk about patents and social justice and, whether it’s directly referenced or not, money, the only numbers of I’ve seen,until recently, have been numbers of doses and aggregate costs.

How much does a single vaccine dose cost?

A Sunday, April 11, 2021 article by Krassen Nikolov for EURACTIV provides an answer about the cost in one region, the European Union,

“Pfizer cost €12, then €15.50. The Commission now signs contracts for €19,50”, Bulgarian Prime Minister Boyko Borissov revealed on Sunday [April 11, 2021].

The European Commission is in talks with Pfizer for the supply of COVID-19 vaccines in 2022 and 2023. Borissov said the contracts provide for €19.50 per dose.

Under an agreement with the vaccine producing companies, the European Commission has so far refused to reveal the price of vaccines. However, last December Belgian Secretary of State Eva De Bleeker shared on Twitter the vaccine prices negotiated by the Commission, as well as the number of doses purchased by her government. Then, it became known that the AstraZeneca jab costs €1.78 compared to €12 for Pfizer-BioNTech.

€12 to €19,50, that’s an increase of over 50%. I wonder how Pfizer is justifying such a hefty increase?

According to a March 16, 2021 article by Swikar Oli for the National Post (a Canadian newspaper), these prices are a cheap pandemic special prices,

A top Pfizer executive told shareholders the company is looking at a “significant opportunity” to raise the price of its Pfizer-BioNTech COVID-19 vaccine.

While addressing investors at the virtual Barclays Global Healthcare Conference last week, Pfizer CFO Frank D’Amelio noted they could raise prices when the virus becomes endemic, meaning it’s regularly found in clusters around the globe, according to a transcript of the conference posted on Pfizer’s website.

Current vaccine pricing models are pandemic-related, D’Amelio explained. After the pandemic is defeated and “normal market conditions” arrive, he noted the window would open for a “significant opportunity…from a pricing perspective.”

“So the one price that we published is the price with the U.S. of $19.50 per dose. Obviously, that’s not a normal price like we typically get for a vaccine, $150, $175 [emphasis mine] per dose,” he said, “So pandemic pricing.”

If I remember it rightly, as you increase production, you lower costs per unit. In other words, it’s cheaper to produce one dozen than one, which is why your bakery charges you less money per bun or cake if you purchase by the dozen.

During this pandemic, Pfizer has been producing huge amounts of vaccine, which they would not expect to do should the disease become endemic. As Pfizer has increased production, I would think the price should be dropping but according to the Bulgarian prime minister, it’s not.

They don’t seem to be changing the vaccine as new variants arrive. So, raising the prices doesn’t seem to be linked to research issues and as for the new production facilities, surely those didn’t cost billions.

Canada and COVID-19 money

Talking about money, Canada has a COVDI-19 billionaire according to a December 23, 2020 article (Meet The 50 Doctors, Scientists And Healthcare Entrepreneurs Who Became Pandemic Billionaires In 2020) by Giacomo Tognini for Forbes.

I have a bit more about Carl Hansen (COVID-19 billionaire) and his company, AbCellera, in my December 30, 2020 posting.

I wonder how much the Canadian life sciences community has to do with Canada’s hesitancy over a COVID-19 vaccine patent rights waiver.

Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist

I’ll start off with the COVID-19 billionaire since I imagine that excites the most interest.

AbCellera billionaire

No less an authority than the business magazine Forbes has produced a list of COVID-19 billionaires in its December 23, 2020 article (Meet The 50 Doctors, Scientists And Healthcare Entrepreneurs Who Became Pandemic Billionaires In 2020) by Giacomo Tognini (Note: Links have been removed),

Nearly a year after the first case of Covid-19 was reported in the Chinese city of Wuhan in December 2019, the world could be nearing the beginning of the end of a pandemic that has killed more than 1.7 million people. Vaccination for Covid-19 is underway in the United States and the United Kingdom, and promising antibody treatments could help doctors fight back against the disease more effectively. Tied to those breakthroughs: a host of new billionaires who have emerged in 2020, their fortunes propelled by a stock market surge as investors flocked to companies involved in the development of vaccines, treatments, medical devices and everything in between.

Altogether, Forbes found 50 new billionaires in the healthcare sector in 2020. …

Carl Hansen

Net worth: $2.9 billion

Citizenship: Canada

Source of wealth: AbCellera

Hansen is the CEO and cofounder of Vancouver-based AbCellera, a biotech firm that uses artificial intelligence and machine learning to identify the most promising antibody treatments for diseases. He founded the company in 2012. Until 2019 he also worked as a professor at the University of British Columbia, but shifted to focus full-time on AbCellera. That decision seems to have paid off, and Hansen’s 23% stake earned him a spot in the billionaire club after AbCellera’s successful listing on the Nasdaq on December 11. The U.S. government has ordered 300,000 doses of bamlanivimab, an antibody AbCellera discovered in partnership with Eli Lilly that received FDA approval as a Covid-19 treatment in November [2020].

Hansen was a professor at the University of British Columbia (UBC) where he founded AbCellera. From https://innovation.ubc.ca/about/news/spin-company-abcelleras-antibody-discovery-leads-covid-19-treatment (Note: A link has been removed),

AbCellera, a local biotechnology company founded at UBC, has developed a method that can search immune responses more deeply than any other technology. Using a microfluidic technology developed at the Michael Smith Laboratories, advanced immunology, protein chemistry, performance computing, and machine learning, AbCellera is changing the game for antibody therapeutics.

I believe a great deal of research that is commercialized was initially funded by taxpayers and I cannot recall any entrepreneurs here in Canada or elsewhere acknowledging that help in a big way. Should you be able to remember any comments of that type, please do let me know in the Comments.

Just prior to this financial bonanza, AbCellera was touting two new board members, John Montalbano on Nov. 18, 2020 and Peter Thiel on Nov. 19, 2020.

Here’s a bit about Mr. Montalbano from a Nov. 18, 2020 AbCellera news release (Note: A link has been removed),

November 18, 2020 – AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, today announced the appointment of John Montalbano to its Board of Directors. Mr. Montalbano will serve as the Chair of the Audit Committee of the Board of Directors.

Mr. Montalbano is Principal of Tower Beach Capital Ltd. and serves on the boards of the Canada Pension Plan Investment Board, Aritzia Inc., and the Asia Pacific Foundation of Canada. His previous appointments include the former Vice Chair of RBC Wealth Management and CEO of RBC Global Asset Management (RBC GAM). When Mr. Montalbano retired as CEO of RBC GAM in 2015, it was among the largest 50 asset managers worldwide with $370 billion under management and offices in Canada, the United States, the United Kingdom, and Hong Kong.

Montalbano has been on this blog before in a Nov. 4, 2015 posting. If you scroll down to the subsection “Justin Trudeau and his British Columbia connection,” you’ll see mention of Montalbano’s unexpected exit as member and chair of UBC’s board of governors.

The next board member to hop on the proverbial path to riches was announced in a Nov. 19, 2020 AbCellera news release,

AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, today announced the appointment of Peter Thiel to its Board of Directors.

“Peter has been a valued AbCellera investor and brings deep experience in scaling global technology companies,” said Carl Hansen, Ph.D., CEO of AbCellera. “We share his optimistic vision for the future, faith in technological progress, and long-term view on company building. We’re excited to have him join our board and look forward to working with him over the coming years.”

Mr. Thiel is a technology entrepreneur, investor, and author. He was a co-founder and CEO of PayPal, a company that he took public before it was acquired by eBay for $1.5 billion in 2002. Mr. Thiel subsequently co-founded Palantir Technologies in 2004, where he continues to serve as Chairman. As a technology investor, Mr. Thiel made the first outside investment in Facebook, where he has served as a director since 2005, and provided early funding for LinkedIn, Yelp, and dozens of technology companies. He is a partner at Founders Fund, a Silicon Valley venture capital firm that has funded companies including SpaceX and Airbnb.

“AbCellera is executing a long-term plan to make biotech move faster. I am proud to help them as they raise our expectations of what’s possible,” said Mr. Thiel.

Some Canadian business journalists got very excited over Thiel’s involvement in particular. Perhaps they were anticipating this December 10, 2020 AbCellera news release announcing an initial public offering. Much money seems to have been made not least for Mr. Montalbano, Mr. Thiel, and Mr. Hansen.

As for Mr. Thiel and taxes, I don’t know for certain but can infer that he’s not a big fan from this portion of his Wikipedia entry,

Thiel is an ideological libertarian,[108] though more recently he has espoused support for national conservatism[109] and criticized libertarian attitudes towards free trade[110] and big tech.[109]

My understanding is that libertarians object to taxes and prefer as little government structure as possible.

In any event, it seems that COVID-19 has been quite the bonanza for some people. If you’re curious you can find out more about AbCellera here.

Onto Avo Media and how it has contributed to the AbCellera story.

Avo Media, The Tyee, and Science Telephone

Vancouver (Canada)-based Avo Media describes itself this way on its homepage,

We make documentary, educational, and branded content.

We specialize in communicating science and other complex concepts in a clear, engaging way.

I think that description boils down to videos and podcasts. There’s no mention of AbCellera as one of their clients but they do list The Tyee, which in a July 1, 2020 posting (The Vancouver Company Turning Blood into a COVID Treatment: A Tyee Video) by Mashal Butt hosts a video about AbCellera,

The world anxiously awaits a vaccine to end the pandemic. But having a treatment could save countless lives in the meantime.

This Tyee video explains how Vancouver biotech company AbCellera, with funding from the federal government, is racing to develop an antibody-based therapy treatment as quickly as possible.

Experts — immunologist Ralph Pantophlet at Simon Fraser University, and co-founder and COO of AbCellera Véronique Lecault — explain what an antibody treatment is and how it can protect us from COVID-19.

It is not a cure, but it can help save lives as we wait for the cure.

This video was made in partnership with Vancouver’s Avo Media team of Jesse Lupini, Koby Michaels and Lucas Kavanagh.

It’s a video with a good explanation of AbCellera’s research. Interestingly, the script notes that the Canadian federal government gave the company over $175M for its COVID-19 work.

Why The Tyee?

While Avo Media is a local company, I notice that Jessica Yingling is listed in the final credits for the video. Yingling founded Little Dog Communications, which is based in both California and Utah. If you read the AbCellera news releases, you’ll see that she’s the media contact.

Is there a more unlikely media outlet to feature a stock market star, which probably will be making billions of dollars from this pandemic, than The Tyee? Politically, its ideology could be described as the polar opposite to libertarian ideology.

I wonder what the thought process was for the media placement and how someone based in San Diego (check out her self description on this Twitter feed @jyingling) came up with the idea?

Science Telephone

Avo Media’s latest project seems to be a podcast series, Science Telephone (this link is to the Spotify platform). Here’s more about the series and the various platforms where episodes can be found (from the Avo Media, Our Work, Science Telephone webpage) ,

Science Telephone is a new podcast that tests how well the science holds up when comedians get their hands onto it

Laugh while you learn, as the classic game of telephone is repurposed for scientific research. Each episode, one scientist explains their research to a comedian, who then has to explain it to the next comedian, and so on until it’s almost unrecognizable. See what sticks and what changes, with a rotating cast of brilliant scientists and hysterical comedians.

See a preview of the show below, or visit www.sciencetelephone.com to subscribe or listen to past episodes.

Science telephone is available on all the usual podcast platforms, including Apple Podcasts and Google Podcasts

I have included the Science Telephone preview here,

As we move towards the end of this year and this pandemic, it’s time to enjoy a little science comedy.